Using our proprietary design platform, TollereBio provides cutting edge solutions for advancing vaccine efficacy by engineering accessible, cost-effective TLR adjuvants.
TollereBio sets a new standard for vaccine adjuvant technology. Using transformative technologies, we develop adjuvants for prophylactic and therapeutic vaccines that are efficacious and safe.
In its Latin derivative, tollere means both to “raise,” and to “destroy” – two opposing forces that are an apt description for what adjuvants can do for vaccines.
TollereBio is driven by our proprietary BECC technology platform which signals through toll-like receptor 4 (TLR4).
Our adjuvants are rationally designed using the engineering of biosynthetic pathways to select structures with unique properties. This enables adjuvants selected with specific immune responses to enhance both prophylactic and therapeutic vaccines.
Learn more about BECC compounds:
NIH Vaccine Adjuvant Compendium
TollereBio's adjuvants offer a cost effective way of increasing the effectiveness of vaccines.
That's TollereBio. Learn more about the founders and the Scientific Advisory Board at the link below.
We’re here to succeed, together. TollereBio is looking for partnerships with other pharmaceutical and biotech companies to enhance product development and find rapid solutions for global needs.
Reach out for more information.